30 September 2011 : The Biosafety Advisory Council issues a positive advice (with conditions) for this trial.
Trial reference:
A Phase IIb/III randomized, double-blind, placebo-controlled study comparing first-line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC)